Craig Sewell, DO
Allergy & Immunology · Indianapolis, INNPI 1346771839
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,348 of the $4,448 with a category attached, or 75.3%. 27 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 30.8% of the total. 2025 is the largest year on record at $2,131, more than ten times the $60 reported in 2019. That places this record below the midpoint for allergy & immunology clinicians in IN, where the typical reported total is $4,393.
Across 149 payments — averaging $29.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- AstraZeneca$502
- CSL Behring$386
- GSK$364
- Sanofi$274
- Galderma Laboratories, L.p.$229
- plus $1K from 21 others
What the payments were for
- Consulting fees$1,10025%
- Food & beverage$3,34875%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $1,371 |
| AstraZeneca | 19 | $502 |
| CSL Behring | 9 | $386 |
| GSK | 18 | $364 |
| Sanofi | 11 | $274 |
| Galderma Laboratories, L.p. | 4 | $229 |
| Novartis | 11 | $201 |
| Regeneron Healthcare Solutions, Inc. | 6 | $168 |
| Teva Pharmaceuticals USA, Inc. | 19 | $163 |
| Kaleo, Inc. | 7 | $104 |
| Biocryst US Sales Co., LLC | 4 | $80 |
| Amgen(2 entities) | 4 | $77 |
| Vifor Pharma, Inc. | 2 | $66 |
| Octapharma USA, Inc. | 3 | $53 |
| Biocryst Pharmaceuticals, Inc. | 3 | $49 |
| Aimmune Therapeutics, Inc. | 2 | $48 |
| Genentech USA, Inc. | 3 | $46 |
| Pharming Healthcare, Inc. | 2 | $44 |
| Pfizer | 2 | $43 |
| Optinose US, Inc. | 2 | $41 |
| Baxter Healthcare | 1 | $24 |
| Boehringer Ingelheim | 2 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Blueprint Medicines Corporation | 1 | $20 |
| Mylan Specialty L.p. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,448 in reported general payments places this provider in the 50th percentile of 49 allergy & immunology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 62 | $293,625 |
| NucalaMepolizumab | 25 | $107,141 |
| Dupixent PenDupilumab | 15 | $64,189 |
| Dupixent SyringeDupilumab | 15 | $58,461 |
| Epinephrine | 44 | $20,347 |
| XhanceFluticasone Propionate | 17 | $10,847 |
| Ipratropium Bromide | 140 | $5,434 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $3,857 |
| Cromolyn Sodium | 14 | $3,046 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,822 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 19 | $2,334 |
| Azelastine Hcl | 51 | $1,341 |
| Famotidine | 56 | $1,013 |
| Fluticasone Propionate | 55 | $666 |
| Carbinoxamine Maleate | 34 | $420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala | $364 | $107,14125 claims |
| Optinose US, Inc.Xhance | $41 | $10,84717 claims |
| AstraZenecaSymbicort | $502 | $2,82212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 49 allergy & immunology providers in Indiana.
Other allergy & immunology in Indianapolis
- Steven WiseIndianapolis$137K
- Pinkus GoldbergIndianapolis$89K
- Tolly EpsteinIndianapolis$8K
- Leanna Marie GershuniIndianapolis$6K
- Douglas HortonIndianapolis$4K
- Maria Luisa Pilar ErmitanoIndianapolis$4K
- Jillian BelmonteIndianapolis$1K
- Dana AlhaffarIndianapolis$179
- Nabeel FarooquiFishers$1.2M
- David PattersonNoblesville$252K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.